Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-Blind, Placebo-Controlled Single Ascending Dose Escalation Study to Assess the Safety, Pharmacokinetics and Efficacy of SL-1002 in Patients With Limb Spasticity

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled Single Ascending Dose Escalation Study to Assess the Safety, Pharmacokinetics and Efficacy of SL-1002 in Patients With Limb Spasticity

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 31 Oct 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs SIL-1002 (Primary)
  • Indications Muscle spasticity
  • Focus Adverse reactions
  • Acronyms RAISE
  • Sponsors Saol Therapeutics

Most Recent Events

  • 30 Oct 2024 According to a Saol Therapeutics media release, data from this study were presented at the Spasticity X Symposium in Houston, Texas.
  • 30 Oct 2024 Results presented in a Saol Therapeutics Media Release.
  • 19 Sep 2023 According to a Saol Therapeutics media release, topline data from the RAISE Limb Spasticity Trial expected in the second quarter of 2024.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top